PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer

Human Pathology

Volumn 55, Issue , 2016, Pages 182-189

  Li, Zhongwu ^a   Lai, Yumei ^a   Sun, Li ^a   Zhang, Xiaotian ^a   Liu, Ruping ^b   Feng, Guoshuang ^c   Zhou, Lixin ^a   Jia, Lin ^a   Huang, Xiaozheng ^a   Kang, Qiang ^a   Lin, Dongmei ^a   Gao, Jing ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b BEIJING INSTITUTE OF GRAPHIC COMMUNICATION   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

EBV; Gastric cancer; HER2; PD L1; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGRAMMED DEATH 1 LIGAND 1; VIRUS RNA; CD274 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR INVASION; CHI SQUARE DISTRIBUTION; EPSTEIN BARR VIRUS; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; STOMACH TUMOR; TUMOR ASSOCIATED LEUKOCYTE; VIROLOGY;

ANTIGENS, CD274; BIOMARKERS, TUMOR; CHI-SQUARE DISTRIBUTION; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; STOMACH NEOPLASMS;

EID: 84978132196     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2016.05.012     Document Type: Article

References (25)

1. [1] Ferlay, J, Shin, HR, Bray, F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127 (2010), 2893–2917.
2. [2] Paydas, S, Bağır, E, Seydaoglu, G, et al. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol 94 (2015), 1545–1552.
3. [3] Herbst, RS, Soria, JC, Kowanetz, M, et al. Predictive correlates of response to the anti–PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
4. [4] Zheng, Z, Bu, Z, Liu, X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res 26 (2014), 104–111.
5. [5] Muro, K, Bang, Y, Shankaran, V, et al. IBA15A phaseIB study of pembrolizumab (PEMBRO; MK-3475) in patients (PTS) with advanced gastric cancer. Ann Oncol(Suppl. 4), 2014, 10.1093/annonc/mdu438.15.
6. [6] Cancer Genome Atlas Research Network, Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209.
7. [7] Tang, W, Morgan, DR, Meyers, MO, et al. Epstein-Barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profiles. Infect Agent Cancer 28 (2012), 21–35.
8. [8] Zhang, YW, Zhao, XX, Tan, C, et al. Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus–associated gastric carcinomas. Oncotarget 6 (2015), 207–220.
9. [9] Salgado, R, Denkert, C, Demaria, S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26 (2015), 259–271.
10. [10] Radu, OM, Foxwell, T, Cieply, K, et al. HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. Am J Clin Pathol l137 (2012), 583–594.
11. [11] Chan, JA, Blaszkowsky, LS, Enzinger, PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 22 (2011), 1367–1373.
12. [12] de Haas, S, Delmar, P, Bansal, AT, et al. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis 17 (2014), 909–920.
13. [13] Noguchi, E, Saito, N, Kobayashi, M, et al. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep 11 (2015), 3423–3431.
14. [14] Powles, T, Eder, JP, Fine, GD, et al. MPDL3280A (anti–PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
15. [15] Brahmer, JR, Tykodi, SS, Chow, LQ, et al. Safety and activity of anti–PD-L1antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
16. [16] Thompson, ED, Zahurak, M, Murphy, A, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut, 2016 [pii: gutjnl-2015-310839].
17. [17] Ghebeh, H, Barhoush, E, Tulbah, A, et al. FOXP3 + Tregs and B7-H1 +/PD-1 + T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer, 23, 2008, 57.
18. [18] Ahmadzadeh, M, Johnson, LA, Heemskerk, B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high level of PD-1 and are functionally impaired. Blood 114 (2009), 1537–1544.
19. [19] Alsuliman, A, Colak, D, Al-Harazi, O, et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer, 14, 2015, 149.
20. [20] van Beek, J, zur Hausen, A, Klein Kranenbarg, E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 22 (2004), 664–670.
21. [21] Kim, SY, Park, C, Kim, HJ, et al. Deregulation of immune response genes in patients with Epstein-Barr virus–associated gastric cancer and outcomes. Gastroenterology 148 (2015), 137–147.
22. [22] Dong, M, Wang, HY, Zhao, XX, et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1 and PD-L2 in EBV-associated gastric carcinoma. HUM PATHOL 53 (2016), 25–34.
23. [23] Lim, H, Park, YS, Lee, JH, et al. Features of gastric carcinoma with lymphoid stroma associated with Epstein-Barr virus. Clin Gastroenterol Hepatol 13 (2015), 1738–1744.
24. [24] Gu, J, Zheng, L, Wang, Y, et al. Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. Tumour Biol 35 (2014), 5315–5321.
25. [25] Kuo, HY, Yeh, KH, Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review. Anticancer Res 34 (2014), 3695–3699.